Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma


This is a single arm, multi-institution (1) Hackensack Meridian Health at Hackensack, New Jersey (NJ) (2) Jersey Shore Medical Center, Neptune, NJ and (3) Georgetown/Lombardi Cancer Center) phase II study of the combination of pembrolizumab, belantamab, and dexamethasone in patients with triple class refractory multiple myeloma.

SparkCures ID 1307
Trial Phase Phase 1/2
Enrollment 64 Patients
Trial Sponsors
  • Hackensack University Medical Center
Trial Collaborators
  • Merck Sharp & Dohme Corp.
NCT Identifier


Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

US Trial Locations

Please visit the page for historical site information.

View Centers